About US
Contact us
-
BMS' PD-1 drug Opdivo continues on stellar trajectoryThe immuno-oncology drug Opdivo from Bristol-Myers Squibb ($BMY) continued on its charmed path today when the drugmaker cut short another trial for lung cancer because it had nailed its goal for overa2015/4/20
-
Sanofi expands PA vaccine facility to prepare for dengue launchSanofi ($SNY) plans to manufacture its highly anticipateddenguevaccine in a French facility built specifically for the product. ButSanofi Pasteur's vaccine operation in Swiftwater, PA, is also expandi2015/4/17
-
BMS, focused on immuno-oncology, turns Erbitux over to Eli LillyErbituxis one of the top 10 best selling cancer drugs in the world and for years Bristol-Myers Squibb ($BMY) has sold it in the U.S. But Erbitux no longer fits in the sweet spot for Bristol-Myers whic2015/4/17
-
Pfizer's Ibrance shines in latest breast cancer studyPfizer ($PFE) won accelerated approval of Ibrance as a first-line breast cancer treatment in February. Now it says that data in a study of the drug as a second-line treatment was so good that it stopp2015/4/16
-
Gilead's hep C drugs make it king of the hill in U.S. drug salesThe U.S. drug market is the largest in the world and just about every drugmaker wants the biggest piece of it that it can get. For 2014 that honor goes to biotech Gilead Sciences ($GILD), whose hep C2015/4/16
-
Record new drug sales give a mega-boost to U.S. drug spendingGiven the flood of numbers onhepatitis Ctreatment costs, it's no surprise that U.S. drug spending took a leap last year. Given the news on specialty drug prices, it's also no surprise that the biggest2015/4/15
-
Onglyza's label should flag heart failure risks, FDA panel saysAstraZeneca ($AZN) escaped the worst with anFDApanel vote on Onglyza. The agency's expert advisers almost unanimously backed the drug's cardiovascular safety. But the panel also recommended that the d2015/4/15
-
2015’ PHEXTOUR Excipients Application Technology (Asia) Tour Seminar--Jakarta Station2015’PHEXTOURExcipients Application Technology (Asia) Tour Seminar--Jakarta Station,was successfully held at Hotel Ciputra on 7 April,2015. The seminar was organized by Phexcom and MegaSetia,co-org2015/4/14
-
Actavis chairman joins Zoetis board under deal with activist investor AckmanPfizer ($PFE) spinoff Zoetis ($ZTS), the animal health company, added a second director to its board under a deal it reached earlier this year with activist investorBill Ackmanand his firm Pershing Sq2015/4/14
-
Valeant CEO's 2014 pay pales in comparison to new EVP's $50M-plusValeant Pharmaceuticals ($VRX) CEOJ. Michael Pearsontook down more than $10 million last year, including a whopping $8 million in incentive pay. But the real surprises in the company's 2015 proxy stat2015/4/14